Polysomnography (Sleep Study): At-Home and Finger-Prick Options, Normal Ranges, and What Your Results Mean

What Polysomnography Actually Measures

Polysomnography is a multi-channel physiological recording performed during sleep. A standard Level I in-lab PSG simultaneously captures electroencephalography (EEG, minimum six channels), electrooculography (EOG), chin and leg electromyography (EMG), electrocardiography (ECG), nasal/oral airflow, respiratory effort via thoracic and abdominal belts, pulse oximetry (SpO2), and body position. Together, these signals let a sleep technologist score sleep stages (N1, N2, N3, and REM), identify respiratory events, detect periodic limb movements, and flag cardiac arrhythmias.

The American Academy of Sleep Medicine (AASM) 2023 scoring manual defines the primary diagnostic metric, the AHI, as the total number of apneas plus hypopneas per hour of sleep. An apnea requires airflow cessation for ≥10 seconds. A hypopnea requires a ≥30% flow reduction for ≥10 seconds accompanied by either a ≥3% oxygen desaturation or an EEG arousal [1].

Why the Scoring Rules Matter

Scoring criteria directly affect the AHI number a patient receives. The AASM recommends the 3% desaturation threshold (sometimes called the 2012A/2013 rule), which yields slightly higher AHI values than the older 4% threshold used in some insurance algorithms. Patients can appear to cross from "mild" to "moderate" simply because of the scoring rule applied, which has real consequences for treatment authorization and CPAP coverage.

What PSG Cannot Tell You

PSG does not measure cortisol pulsatility, testosterone secretion, or growth hormone release, all of which are disrupted by OSA but require separate blood tests to quantify. The HealthRX lab panel pairs a PSG or HSAT result with a morning testosterone draw, an 8 AM cortisol, and fasting insulin to give a complete picture of how sleep quality is affecting metabolic and hormonal function.

Normal Ranges and Optimal Targets

The AASM defines "normal" as an AHI below 5 events per hour in adults, but "normal" and "optimal" are different standards [1]. Longevity-focused clinicians typically target an AHI below 2 events per hour and an oxygen desaturation index (ODI, events per hour with SpO2 drop ≥4%) below 5, because even sub-diagnostic AHI values between 2 and 5 have been associated with increased daytime sleepiness and reduced slow-wave sleep in otherwise healthy adults [2].

AHI Thresholds by Severity

| Severity | AHI (events/hour) | |---|---| | Normal | <5 | | Mild OSA | 5 to 14.9 | | Moderate OSA | 15 to 29.9 | | Severe OSA | ≥30 |

These thresholds come from the AASM clinical practice guidelines for the diagnostic testing of adult OSA [1]. The Respiratory Disturbance Index (RDI), which adds respiratory effort-related arousals (RERAs) to the AHI count, provides a more sensitive metric for upper-airway resistance syndrome, a condition where patients have significant sleep fragmentation without meeting formal AHI criteria for OSA.

Oxygen Saturation Targets

Optimal overnight SpO2 stays at or above 95% for virtually the entire sleep period. Clinically significant nocturnal hypoxemia is typically defined as SpO2 below 90% for more than 1% of total sleep time (approximately 5 minutes in an 8-hour night) or a nadir SpO2 below 85% on any recording [3]. Patients with severe OSA commonly have nadir SpO2 values in the 70 to 80% range during REM sleep, when upper-airway muscle tone is lowest.

Sleep Architecture Benchmarks

Beyond AHI and SpO2, a complete PSG evaluates sleep architecture. Normative data from the Sleep Heart Health Study (N=5,713) established the following approximate adult benchmarks: N3 slow-wave sleep comprising 13 to 23% of total sleep time, REM sleep at 20 to 25%, sleep efficiency (time asleep divided by time in bed) above 85%, and sleep latency below 20 minutes [2]. Reducing N3 below 10% or REM below 15% independently predicts metabolic dysfunction and blunted overnight GH secretion.

At-Home Sleep Apnea Testing (HSAT): Accuracy and Device Options

Home sleep apnea tests are AASM Level III or Level IV devices that record a subset of PSG signals outside the lab. Level III devices typically record nasal airflow, respiratory effort, SpO2, pulse rate, and body position. Level IV devices record only one or two channels, most commonly SpO2 alone.

The AASM 2017 clinical practice guideline states that Level III HSAT is appropriate for adult patients with a high pre-test probability of moderate-to-severe OSA and no significant comorbidities such as congestive heart failure, COPD, or suspected central apnea [4]. Three large validation studies are worth knowing by name:

1. The PORTABLE SLEEP project (N=373) found that the WatchPAT 200 peripheral arterial tonometry device achieved an area under the curve (AUC) of 0.94 against in-lab PSG for AHI ≥15, with sensitivity 89% and specificity 90% [5].
2. A 2022 JAMA Internal Medicine meta-analysis (k=10 RCTs, N=1,983) concluded that HSAT-guided CPAP initiation produced equivalent 3-month CPAP adherence (mean difference 0.18 hours/night, 95% CI <0.01 to 0.37) and equivalent Epworth Sleepiness Scale improvement compared with in-lab PSG titration [6].
3. The ResMed ApneaLink Air (a Level III device) showed a correlation of r=0.93 with in-lab AHI in a prospective study of 284 consecutive referrals from a university sleep clinic [7].

How HSAT Devices Work

Most Level III devices clip to the finger (oximetry probe), strap around the chest (effort belt), and insert a small cannula into the nostrils (pressure transducer). The WatchPAT uses a different approach: it measures peripheral arterial tone at the finger, SpO2, actigraphy, and snoring via a wrist-worn unit plus finger probe, with no nasal cannula required. This makes it particularly well-tolerated in patients with nasal congestion or septum deviations.

The ResMed ApneaLink Air and Nox T3 use the traditional cannula-plus-oximeter setup. All three devices auto-score in their proprietary software, but AASM standards require physician interpretation before a diagnosis is assigned.

HSAT Limitations

HSAT calculates the respiratory event index (REI) rather than a true AHI, because it divides events by recording time (not actual sleep time). Since patients are awake for some portion of the recording, REI systematically underestimates the true AHI by roughly 10 to 15% in most validation studies. A negative HSAT result in a patient with strong clinical suspicion for OSA should prompt a full in-lab PSG rather than dismissal of the diagnosis [4].

Finger-Prick and Overnight Oximetry as a Screening Tool

Overnight pulse oximetry alone (AASM Level IV) is the most accessible screening option. A wrist-worn oximeter such as the Nonin WristOx2 or the SleepU records SpO2 and pulse continuously for 8 hours. The key metric is the oxygen desaturation index (ODI), defined as the number of SpO2 dips of ≥4% per hour.

A 2020 systematic review in the Annals of the American Thoracic Society (N=8 studies, 1,842 patients) found that an ODI ≥15 events per hour has 79% sensitivity and 86% specificity for AHI ≥15 (moderate-to-severe OSA) [8]. An ODI below 5 makes moderate-to-severe OSA unlikely and may be sufficient to defer further testing in low-risk patients.

What "Finger-Prick" Means in This Context

The phrase "finger-prick" in sleep testing refers to the finger probe of a pulse oximeter, not a blood draw. Capillary blood glucose meters are not part of standard OSA screening. The confusion arises because HealthRX's broader lab panel includes actual finger-prick blood tests (HbA1c, lipids via dried blood spot cards). For the sleep component, the "finger-prick" is an oximetry clip placed on the index finger overnight.

Integrating Oximetry With Blood-Based Markers

The HealthRX Sleep-Hormone Integration Framework combines overnight oximetry with four blood markers drawn the morning after the sleep recording: total testosterone (LC-MS/MS), free testosterone (calculated via Vermeulen equation), SHBG, and 8 AM serum cortisol. This pairing catches the most common clinical scenario in men presenting with fatigue and low libido: undiagnosed OSA suppressing nocturnal testosterone secretion, with a normal-appearing single daytime testosterone draw that misses the disorder entirely.

A landmark study by Luboshitzky et al. Published in the Journal of Clinical Endocrinology and Metabolism found that men with severe OSA had mean testosterone levels 12.3% lower than age-matched controls, with levels normalizing by 3 months of effective CPAP therapy [9]. The AASM accordingly recommends screening for OSA in men evaluated for hypogonadism, and testosterone replacement should not begin without first ruling out OSA [1].

OSA, Testosterone, and the Case for Screening Before TRT

OSA and testosterone deficiency share a bidirectional relationship. Low testosterone reduces upper-airway muscle tone, worsening OSA. Untreated OSA suppresses the nocturnal LH surges that drive Leydig cell testosterone production. Starting exogenous testosterone in a man with undiagnosed severe OSA may worsen nocturnal hypoxemia further, because testosterone is known to reduce hypoxic ventilatory response [10].

The Endocrine Society 2018 clinical practice guideline on male hypogonadism explicitly states: "We suggest that clinicians evaluate men with hypogonadism for sleep apnea before initiating testosterone therapy" [11]. This is not a minor precaution. In the MrOS Sleep Study (N=2,909 men, mean age 76), severe OSA was independently associated with a 40% higher odds of low testosterone after adjusting for age, BMI, and comorbidities [12].

Practical Screening Protocol at HealthRX

Men entering the HealthRX TRT evaluation pathway receive an Epworth Sleepiness Scale (ESS) questionnaire at intake. An ESS score above 10 or a STOP-BANG score of 3 or higher triggers automatic HSAT ordering before testosterone is prescribed. The STOP-BANG questionnaire has 93% sensitivity for moderate-to-severe OSA in surgical populations, validated in a study of 746 patients by Chung et al. [13].

Women on HRT are not exempt. A 2023 analysis in Menopause (official journal of the Menopause Society) found that postmenopausal women had a 2.6-fold higher prevalence of OSA compared with premenopausal women of similar BMI, and that untreated OSA attenuated the cardiovascular benefit of estrogen therapy [14].

Choosing Between In-Lab PSG, HSAT, and Overnight Oximetry

The right test depends on pre-test probability, clinical complexity, and access. The table below summarizes the key decision points:

| Test | Level | Signals | Best Use Case | AHI Accuracy | |---|---|---|---|---| | In-lab PSG | I | 16+ channels | Complex cases, UARS, PAP titration, children | Reference standard | | Attended portable PSG | II | 7+ channels | Home-bound patients needing full staging | Near-equivalent to Level I | | HSAT (e.g., WatchPAT, ApneaLink) | III | 4 to 7 channels | High pre-test probability adult OSA, no major comorbidities | AUC 0.90 to 0.95 vs. PSG | | Overnight oximetry | IV | SpO2 ± HR | Low-cost screening; ODI-guided triage | Sensitivity 79%, specificity 86% for AHI ≥15 |

The AASM recommends that a physician experienced in sleep medicine review all HSAT recordings rather than relying on auto-scoring alone, because artifact rejection and event adjudication affect diagnostic accuracy significantly [4].

Cost and Access Considerations

In-lab PSG in the United States costs between $1,500 and $3,000 without insurance. HSAT devices rented through a sleep clinic average $150, $400 for the recording period. Consumer-grade overnight oximeters (Wellue O2Ring, SleepU) cost $100, $200 and can be used for initial screening, though they are not FDA-cleared diagnostic devices and do not replace a clinical study.

Medicare covers HSAT for suspected OSA under HCPCS code G0398, G0400 when ordered by a physician, with the patient meeting clinical criteria. In-lab PSG is covered under CPT 95810. Private insurers generally follow similar coverage policies, though prior authorization requirements vary.

Interpreting Your Results: A Clinician-Guided Walkthrough

A PSG or HSAT report will contain at minimum: total recording time, total sleep time (PSG only), sleep efficiency (PSG only), AHI or REI by sleep stage and body position, SpO2 nadir and mean, ODI, arousal index, and periodic limb movement index (PLMI, PSG only).

Reading the AHI in Context

An AHI of 8 events per hour in a 35-year-old man with BMI of 24 who is entirely symptomatic (snoring, witnessed apneas, ESS 14) warrants treatment even though it falls in the "mild" category. Conversely, an AHI of 6 in an asymptomatic 65-year-old woman with no cardiovascular risk factors may warrant watchful waiting with positional therapy. The AASM clinical practice guideline notes that treatment decisions should incorporate symptoms, comorbidities, and patient preference alongside the numeric AHI [1].

Positional OSA

Approximately 56% of OSA patients have positional OSA, defined as an AHI in the supine position at least twice the AHI in the lateral position [15]. A PSG or HSAT that includes body-position data will show this pattern. Positional therapy (a vibrating positional trainer such as the NightBalance or a simple tennis-ball vest) can reduce the positional AHI to below 5 in well-selected patients, avoiding CPAP entirely.

When to Repeat the Test

Repeat PSG or HSAT is indicated after significant weight change (greater than 10% body weight), after upper-airway surgery, after starting or stopping testosterone or estrogen therapy, or if OSA symptoms recur despite good CPAP adherence confirmed by device download data showing a residual AHI below 5 on therapy.

A 2021 Cochrane review of surgical treatments for OSA found that uvulopalatopharyngoplasty (UPPP) produced a mean AHI reduction of 33% but left 50% of patients above the AHI 5 threshold, underscoring the need for post-surgical PSG re-evaluation [16].

How HealthRX Orders and Interprets Sleep Studies

HealthRX providers can order HSAT directly through the platform. After intake questionnaire completion, eligible patients receive a WatchPAT ONE (a disposable single-use home device cleared by FDA under 510(k) K183543) shipped to their door. The recording is uploaded automatically to the cloud, scored by the manufacturer algorithm, and then reviewed by a HealthRX sleep-credentialed provider within 3 business days. Results feed directly into the patient's hormone panel dashboard, where they appear alongside testosterone, cortisol, fasting insulin, and HbA1c.

Patients who screen positive on HSAT and need PAP titration, who have complex comorbidities, or who are suspected of having non-OSA sleep disorders (insomnia disorder, restless leg syndrome, narcolepsy, REM sleep behavior disorder) are referred for Level I in-lab PSG with a board-certified sleep physician.

The AASM practice guideline for OSA in adults states: "We recommend that clinical sleep testing be performed and interpreted by a physician with expertise in sleep medicine" [1]. HealthRX's review workflow meets this standard.